Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated.
John L Robinson, Edward B Lee, Sharon X Xie...
https://pubmed.ncbi.nlm.nih.gov/29878075Actively Recruiting
Age: 30Years - 95Years
All Genders
ID06529744
Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling
Led by University Health Network, Toronto · Updated on 2025-11-20
500
Participants Needed
4
Research Sites
52 weeks
Total Duration
On this page
Sponsors
U
University Health Network, Toronto
Lead Sponsor
S
Sunnybrook Health Sciences Centre
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are working to develop a model that can predict how diseases progress in patients with various neurodegenerative conditions, including Mild Cognitive Impairment (MCI) and different types of dementia such as Alzheimer's Disease, Lewy Body Disease, Vascular Dementia, and Frontotemporal Dementia. The study aims to improve diagnosis and forecasting of disease progression to better support patients with early dementia or cognitive impairment. The study will collect and evaluate several types of information from participants, including brain imaging with MRI, samples of blood and cerebrospinal fluid, skin biopsies, and assessments of cognitive ability and behavior through questionnaires. These tests will be done at baseline and during follow-up visits to gather detailed data on disease characteristics and progression. Participants will undergo evaluations at the start of the study, then again at 6 months and 1 year to monitor changes in cognition and other markers. The research team will analyze cognitive performance, DNA methylation from blood samples, neurodegenerative protein levels in fluids and skin, and brain structure and function via MRI. Participants will be monitored over time to provide data that may help predict how their condition changes.
CONDITIONS
Brief Title
Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling
Who Can Participate
Age: 30Years - 95Years
All Genders
Eligibility Criteria
You may qualify if you...
- Possible or probable diagnosis of mild cognitive impairment or early dementia
- Age between 30 and 95 years
- Have a study partner who has regular weekly contact with the participant
- Be able to complete most study procedures as judged by the site investigator
You will not qualify if you...
- Unable to complete the majority of assessments as judged by the site investigator
- Symptoms believed to be caused by conditions other than neurodegeneration based on investigator's evaluation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Baseline assessments
Participants undergo various tests including brain MRI, blood and cerebrospinal fluid sampling, skin biopsy, cognitive assessments, and behavioral questionnaires to evaluate their condition.
1 visit (in-person)
Long-term Monitoring
Duration - 1 year
Participants are followed over time with repeated cognitive and biomarker assessments to monitor disease progression.
Visits at 6 months and 1 year (in-person)
Trial Site Locations
Total: 4 locations
1
Baycrest
North York, Ontario, Canada, M6A 2E1
Not Yet Recruiting
2
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Not Yet Recruiting
3
Toronto Western Hospital, University Health Network
Toronto, Ontario, Canada, M5T 2S8
Actively Recruiting
4
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M6J 1H1
Not Yet Recruiting
Loading map...
Research Team
C
Claudia Clementi, HBSc
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Friend, Foe or Both? Immune Activity in Alzheimer's Disease.
Georgia R Frost, Lauren A Jonas, Yue-Ming Li
https://pubmed.ncbi.nlm.nih.gov/31920620DNA Methylation Clocks and Their Predictive Capacity for Aging Phenotypes and Healthspan.
Tessa Bergsma, Ekaterina Rogaeva
https://pubmed.ncbi.nlm.nih.gov/32743556DNA methylation age-acceleration is associated with disease duration and age at onset in C9orf72 patients.
Ming Zhang, Maria Carmela Tartaglia, Danielle Moreno...
https://pubmed.ncbi.nlm.nih.gov/28439722DNA methylation age acceleration is associated with ALS age of onset and survival.
Ming Zhang, Paul M McKeever, Zhengrui Xi...
https://pubmed.ncbi.nlm.nih.gov/32146547Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.
Elisabeth H Thijssen, Renaud La Joie, Amy Wolf...
https://pubmed.ncbi.nlm.nih.gov/32123386Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease.
Shorena Janelidze, David Berron, Ruben Smith...
https://pubmed.ncbi.nlm.nih.gov/33165506Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.
Nicholas J Ashton, Tharick A Pascoal, Thomas K Karikari...
https://pubmed.ncbi.nlm.nih.gov/33585983NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Clifford R Jack, David A Bennett, Kaj Blennow...
https://pubmed.ncbi.nlm.nih.gov/29653606A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.
Clifford R Jack, David A Bennett, Kaj Blennow...
https://pubmed.ncbi.nlm.nih.gov/27371494